Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
NEW YORK, Dec. 28, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Northern District of Indiana on behalf of investors who purchased Zimmer Biomet Holdings, Inc. (NYSE:ZBH) securities between September 7, 2016 and October 31, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/zimmer-biomet-holdings. There is no cost or obligation to you.
According to the complaint, during the Class Period, defendants issued materially false and/or misleading statements and/or failed to disclose: 1) issues within the supply chain caused a decline in order fulfillment, particularly within the knee and hip portfolios; 2) as such, Zimmer Biomet would not realize its revenues and profit as expected and; 3) as a result of the above, the Company’s statements regarding its business, operations and prospects, were false and misleading and/or lacked a reasonable basis.
If you suffered a loss in Zimmer Biomet you have until January 31, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/zimmer-biomet-holdings.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
